Glucan particles for selective delivery of siRNA to phagocytic cells in mice

Author:

Tesz Gregory J.1,Aouadi Myriam1,Prot Matthieu1,Nicoloro Sarah M.1,Boutet Emilie1,Amano Shinya U.1,Goller Anca1,Wang Mengxi1,Guo Chang-An1,Salomon William E.1,Virbasius Joseph V.1,Baum Rebecca A.1,O'Connor Mark J.1,Soto Ernesto1,Ostroff Gary R.1,Czech Michael P.1

Affiliation:

1. Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.

Abstract

Phagocytic macrophages and dendritic cells are desirable targets for potential RNAi (RNA interference) therapeutics because they often mediate pathogenic inflammation and autoimmune responses. We recently engineered a complex 5 component glucan-based encapsulation system for siRNA (small interfering RNA) delivery to phagocytes. In experiments designed to simplify this original formulation, we discovered that the amphipathic peptide Endo-Porter forms stable nanocomplexes with siRNA that can mediate potent gene silencing in multiple cell types. In order to restrict such gene silencing to phagocytes, a method was developed to entrap siRNA–Endo-Porter complexes in glucan shells of 2–4 μm diameter in the absence of other components. The resulting glucan particles containing fluorescently labelled siRNA were readily internalized by macrophages, but not other cell types, and released the labelled siRNA into the macrophage cytoplasm. Intraperitoneal administration of such glucan particles containing siRNA–Endo-Porter complexes to mice caused gene silencing specifically in macrophages that internalized the particles. These results from the present study indicate that specific targeting to phagocytes is mediated by the glucan, whereas Endo-Porter peptide serves both to anchor siRNA within glucan particles and to catalyse escape of siRNA from phagosomes. Thus we have developed a simplified siRNA delivery system that effectively and specifically targets phagocytes in culture or in intact mice.

Publisher

Portland Press Ltd.

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference60 articles.

1. RNAi therapeutics: a potential new class of pharmaceutical drugs;Bumcrot;Nat. Chem. Biol.,2006

2. Small silencing RNAs: an expanding universe;Ghildiyal;Nat. Rev. Genet.,2009

3. RNAi-based therapeutics: current status, challenges and prospects;Tiemann;EMBO Mol. Med.,2009

4. RNAi-based therapeutic strategies for metabolic disease;Czech;Nat. Rev. Endocrinol.,2011

5. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?;Grimm;J. Clin. Invest.,2007

Cited by 93 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3